Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy in relapsed/refractory classical Hodgkin lymphoma

MLA

Armand, Philippe, et al. “Five-Year Follow-up of KEYNOTE-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma.” Blood, no. Preprints, Jan. 2023. EBSCOhost, https://doi.org/10.1182/blood.2022019386.

APA

Armand, P., Zinzani, P. L., Lee, H. J., Johnson, N. A., Brice, P., Radford, J., Ribrag, V., Molin, D., Vassilakopoulos, T. P., Tomita, A., von Tresckow, B., Shipp, M. A., Herrera, A. F., Lin, J., Kim, E., Chakraborty, S., Marinello, P., & Moskowitz, C. H. (2023). Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy in relapsed/refractory classical Hodgkin lymphoma. Blood, Preprints. https://doi.org/10.1182/blood.2022019386

Chicago

Armand, Philippe, Pier Luigi Zinzani, Hun Ju Lee, Nathalie A. Johnson, Pauline Brice, John Radford, Vincent Ribrag, et al. 2023. “Five-Year Follow-up of KEYNOTE-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma.” Blood, no. Preprints (January). doi:10.1182/blood.2022019386.